Stocks
Barclays Analyst Raises Amgen Target to $380
Barclays analyst Emily Field has reaffirmed her 'hold' rating on Amgen (AMGN.US) while increasing her target price to $380. This updated prediction comes after a thorough review of the company's performance.
In evaluating Field's performance, TipRanks notes that she boasts a success rate of 45.6% and an average return of 2.0% over the past year. The analyst's ratings are based on her preliminary recommendations, which have been adjusted according to changes in the market.